Marijuana Gum For Fibromyalgia Pain Relief: Would You Try This?


Originally recognized by the American College of Rheumatology in 1990, Fibromyalgia is highly misunderstood among the general population. Predominant in the female population, as high as 7% of the population has been reported, with many more cases going undiagnosed. As awareness of the disease grows, so too is the demand for ways to manage the pain.



What is Fibromyalgia?

Largely characterized by widespread musculoskeletal pain, fibromyalgia also can be accompanied by memory and mood issues, fatigue and trouble sleeping. While much about this disorder remains unknown, experts believe that it affects the way your brain is able to process pain signals by amplifying the body’s pain sensations.
Symptoms include:
  • Extreme and widespread pain
  • Chronic headache
  • Jaw pain
  • Fatigue
  • Disrupted sleep patterns
  • Joint stiffness
  • Difficulty swallowing
  • Bladder and bowel abnormalities
  • Numbness and tingling
While there is no known cure for the disorder, doctors currently prescribe medications to help control the various symptoms associated with fibromyalgia. Medical professionals also cite exercise, stress-reduction, and relaxation as beneficial ways of managing symptoms.

Fibromyalgia and Cannabis

Cannabis has been found to be beneficial in the management of a number of fibromyalgia symptoms including pain relief, better sleep, and increased energy levels.
The use of Cannabis for pain relief has been gaining in popularity recently, as a growing number of Americans become educated on the uses of marijuana as a medical alternative. Peripheral nerves that detect pain sensations in the body contain receptors for cannabinoids, found in cannabis. These cannabinoids work to block the transfer of pain along the peripheral nerves to the brain, effectively managing pain throughout the body.




Marijuana Gum


AXIM Biotechnologies has created a marijuana gum, allowing the user to digest equal parts of both THC and CBD. Chief executive officer Dr. George E. Anastassoy, MD, DDS, MBA explained that the gum allows the patient to bypass the liver, allowing the active ingredients to work faster and more efficiently.

Professor John Zajicek explains that chewing, as opposed to breathing or ingesting the product, means that there is now ‘peak’ as is associated with the more traditional cannabis applications. Chewing itself also carries its own benefits, relieving stress and stimulating the cardiovascular system. It also helps to slow down the loss of cognition that comes with aging. Furthermore, according to Zajicek, chewing gum is considered to be more socially acceptable than ingesting or smoking marijuana.
At this time AXIM holds the patent for their chewing gum product, with one product already on the market. Can Chew Gum is currently on the shelves everywhere that CBD products can be legally carried, marketed as a dietary supplement. The company is also in the testing phase of developing topical CBG treatments that they advise are beneficial both for eczema and psoriasis.

A reality check

Apparently, AXIM owns the patent on chewing gum as a delivery method for cannabinoids and already have one CBD-only product, Canchew gum, marketed as a dietary supplement and sold everywhere CBD products can sit on shelves. AXIM also started trials for a patent-pending CBG topical for exzema and psoriasis. In addition, there are even oral care and cosmetics in their arsenal.

Medical Marijuana, Inc. owns about 46% of AXIM and plans on many more cannabis-related products. They are the Swiss Army knife of cannabis companies, with their hands in everything from international markets to security services. If only it were so simple for the little guys.

AXIM versus GW

Another big medical company hopping on the cannabis bandwagon is GW Pharmaceuticals. Their spraySativex already has approval in 27 countries, though notably not the US. GW’s other flagship, Epidiolex, is fast working its way through FDA approval.



The two differ in their approach to cannabis. GW cultivates its own plants, in order to control genetics and make quality medicine. In contrast, AXIM sources its herb from a deal with the Dutch government, which gives it a significant discount on bulk purchase.

Yet AXIM benefits from the headway made by GW, in that there exists an established “evidence of safety” for the medicine derived from natural cannabis. Unfortunately for the rest of us, the evidence may be good enough for huge companies, but not good enough for the plant itself, according to the FDA and DEA.

Post a Comment

0 Comments